Anti-virals

Anti-virals

GEA supplies solutions for manufacturing inhalable and oral antiviral drugs ranging from blending, spray drying and particle engineering to continuous manufacturing.

Manufacturing Anti-virals

Antiviral medications help the body to fight off harmful viruses such as influenza, chickenpox and the human immunodeficiency virus (HIV), to name a few. The drugs can ease symptoms and shorten the length of a viral infection. Antivirals also lower the risk of getting or spreading viruses that cause herpes and HIV. One approved antiviral treats the coronavirus that causes COVID-19.

Antiviral drugs are also preventive. They can protect you from getting viral infections or spreading a virus to others. They come in many formats, including tablets, intravenous solutions, liquids and inhaled powders.

For inhalable versions, GEA understands that homogeneity and stability are key factors. Our dry powder blending, spray drying and particle engineering capabilities ensure that the production of free-flowing, aerodynamic particles at the correct size is achievable at the scale you need.

And, with the ongoing development of oral anti-viral medications, particularly as a result of the COVID-19, pandemic, there is increased interest in the use of continuous manufacturing to accelerate process design and product optimization.

For example, the compact and fully integrated ConsiGma® 4.0 platform has been designed to transfer powder into coated tablets in a shorter time frame. Plus, by combining Quality by Design (QbD) principles with Design of Experiments (DoE), it enables operators to explore the design space in a quick and easy way and expedite time-to-market. 

Prodotti e tecnologie

{{count}} su {{total}}

Resta in contatto con le innovazioni e le storie GEA iscrivendoti alle news di GEA.

Registrati

Siamo qui per aiutarti! Solo pochi dettagli e saremo in grado di rispondere alla tua richiesta.

Contattaci